CoChat

Masquerader: High Mobility Group Box-1 and Cancer

The DOI matches its Crossref record; 126 of the 128 references it cites were found in a registry or an index.

Abstract

Since its identification a third of a century ago, the high-mobility group box-1 (HMGB1) protein has been linked to varied diverse cellular processes, including release from necrotic cells and secretion by activated macrophages engulfing apoptotic cells. Initially described as solely chromatin-associated, HMGB1 was additionally discovered in the cytoplasm of several types of cultured mammalian cells 6 years later. In addition to its intracellular role, HMGB1 has been identified extracellularly as a putative leaderless cytokine and differentiation factor. In the years since its discovery, HMGB1 has also been implicated in disease states, including Alzheimer's, sepsis, ischemia-reperfusion, arthritis, and cancer. In cancer, overexpression of HMGB1, particularly in conjunction with its receptor for advanced glycation end products, has been associated with the proliferation and metastasis of many tumor types, including breast, colon, melanoma, and others. This review focuses on current knowledge and speculation on the role of HMGB1 in the development of cancer, metastasis, and potential targets for therapy.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-06-1953

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 126 references

Research works printed but not linked: 1

  1. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: Friend and foe. Cytokine Growth Factor Rev 2006;17:189–201. · DOI · Paper page

Cited by

See all 355

Metadata

Authors
Ellerman, J. E., Brown, C. K., de Vera, M., Zeh, H. J., Billiar, T., Rubartelli, A., & Lotze, M. T.
Affiliations
  • University of Pittsburgh Medical Center (US)
  • 1Department of Surgery, Molecular Genetics, and Biochemistry, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania and
  • 2Cell Biology Unit, Instituto Nazionale per la Ricerca sul Cancro y Genoa, Italy
Venue
Clinical Cancer Research
Published
2007-05-15
Volume
13
Issue
10
Pages
2836-2848
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2016000295
Cited by
355
References
128
Citations by year
2026: 1 · 2025: 4 · 2024: 6 · 2023: 10 · 2022: 12 · 2021: 9 · 2020: 17 · 2019: 14 · 2018: 17 · 2017: 28 · 2016: 22 · 2015: 30 · 2014: 27 · 2013: 37 · 2012: 32
FWCI
3.04
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
American Society of Hematology
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › S100 Proteins and Annexins
  • Life Sciences › Immunology and Microbiology › Immunology › Galectins and Cancer Biology
Keywords
HMGB1, high mobility group box 1, cancer, metastasis, RAGE, receptor for advanced glycation end products, extracellular HMGB1, tumor cell proliferation, therapeutic target
MeSH terms
Cell Movement, Cell Nucleus, Humans, Neoplasms, Receptors, Cell Surface, Signal Transduction, HMGB1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Masquerader: High Mobility Group Box-1 and Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-06-1953
The paper
Ellerman, J. E., Brown, C. K., de Vera, M., Zeh, H. J., Billiar, T., Rubartelli, A., & Lotze, M. T. (2007). Masquerader: High Mobility Group Box-1 and Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-06-1953

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.